Results 281 to 289 of about 188,791 (289)

Rituximab

Reactions Weekly, 2013
openaire   +2 more sources

The case against rituximab maintenance

Nature Reviews Clinical Oncology, 2009
Bruce D Cheson
exaly  

Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial

Lancet, The, 2016
Duncan Porter, Claudia-Martina Messow, James Dale   +2 more
exaly  

Rituximab

Reactions Weekly, 2008
openaire   +1 more source

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

Lancet, The, 2013
David Cunningham, Paul Mouncey, Anton Kruger   +2 more
exaly  

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

New England Journal of Medicine, 2018
Ranjana H Advani, Leslie L Popplewell, Nancy L Bartlett   +2 more
exaly  

Rituximab

Reactions Weekly, 2019
openaire   +2 more sources

Rituximab

Reactions Weekly
openaire   +1 more source

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Lancet, The
Matthew Ku, Haifaa Abdulhaq, Chan Yoon Cheah   +2 more
exaly